权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

EVALUATION OF BOTANICALS FOR H .PYLORI INFECTIONS

植物药治疗幽门螺杆菌感染的评估

基本信息

批准号：
6488864
负责人：
GAIL B MAHADY
金额：
$ 19.41万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
起止时间：
2001-02-01 至 2002-12-31
项目状态：
已结题

项目摘要

DESCRIPTION (Applicant's Abstract): After more than a decade of research and controversy, it has been conclusively demonstrated that Helicobacter pylori is the main cause of peptic ulcer disease. High infection rates around the world pose serious health and economic problems. In the U. S. alone, 500,000 new cases, and 4 million recurrences are reported annually, at a cost of $3 to $4 billion dollars. Current therapies for H. pylori infections consist of combinations of antibiotics, and H2 blockers. However, due to the serious adverse reactions, patient compliance is low, leading to the development of antibiotic resistance. Thus, new approaches to the treatment H. pylori infections are urgently needed. For thousand of years traditional systems of medicine have successfully used botanicals (plant-based medicines) for the treatment of dyspepsia, gastritis and peptic ulcers. However, most of these botanicals have not been systematically screened for anti-H. pylori activity. This proposal describes an international, multidisciplinary approach to investigating botanical extracts for the treatment and prevention of H. pylori infections. The work is designed to generate sufficient preliminary data to serve as the basis of more definitive studies. The major goal of the project is to identify and standardize botanical extracts and combinations of extracts for the treatment of H. pylori infections. To accomplish this goal, the project involves (1) selection and procurement of botanicals to be tested (2) extraction of the source materials, (3) short-term in vitro and fn vivo testing biological studies to determine activity and mechanistic information (4) in vivo evaluations to establish safety and efficacy, and (5) determination of the major chemical constituents for standardization of the active extracts. Over the two-year period, approximately 60 new botanicals will be selected and evaluated for antibacterial activity against H. pylori. The list of high priority botanicals for testing will be generated based on data analysis from the Napralertsm database, Medline, German Commission E Monographs and other data sources. The success of this method for plant selection is seen in our preliminary results where an initial testing of 25 identified botanicals led to 13 active extracts. In this project, the botanicals will be procured and extracts prepared. The botanical extracts will be subjected to in vitro bioassay protocols using 15 H. pylori strains. Active extracts will be utilized for in vivo studies. The long-term objectives are to develop safe and effective botanical extracts for the treatment and prevention of H. pylori infections.

描述（申请人摘要）：经过十多年的研究和有争议的是，已经明确表明幽门螺杆菌是消化性溃疡的主要病因。世界各地的高感染率造成严重的健康和经济问题。在美国S.仅50万新每年报告400万例复发病例，费用为3至4美元亿美元目前H.幽门螺杆菌感染包括抗生素和H2阻断剂的组合。然而，由于严重的不良反应，患者依从性低，导致发展抗生素耐药性因此，新的方法来治疗H。幽门感染是迫切需要的。几千年来，传统的医学已经成功地使用植物药（植物为基础的药物），治疗消化不良、胃炎和消化性溃疡。然而，其中大多数尚未系统地筛选抗H. pylori活性该提案描述了一种国际多学科方法，研究植物提取物用于治疗和预防H.幽门感染.这项工作旨在生成足够的初步数据，作为更明确研究的基础。该项目的主要目标是鉴定和标准化植物提取物和提取物的组合， H.幽门感染。为了实现这一目标，该项目涉及（1）选择和采购待测植物（2）原材料的提取，（3）短期体外和体内试验生物学研究，以确定活动和机制信息（4）体内评价，以确定安全性和有效性，和（5）确定用于活性提取物标准化的主要化学成分。超过在两年的时间里，将选择大约60种新的植物，评价对H.幽门。高的名单将根据以下数据分析生成用于测试的优先植物药： Napralertsm数据库、Medline、German Commission E Monographs和其他数据源这种植物选择方法的成功在我们的初步结果，其中25个确定的植物的初步测试导致， 13活性提取物。在这个项目中，将采购植物药，制备浸提液。植物提取物将在体外进行生物测定方案使用15H. pylori菌株。将使用活性浸提液用于体内研究。长期目标是开发安全有效的用于治疗和预防H.幽门感染